XBiotech (XBIT) 10-Q2024 Q1 Quarterly report

Filed: 10 May 24, 11:27am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: acceleration, Additionally, agreed, cancer, cap, Chairman, comprised, Converible, conversion, converted, convertible, critical, declare, disaggregated, disinterested, distributed, domestic, drop, estate, expansion, feature, Founder, issuable, John, Lane, loan, negotiated, Official, ownership, preceding, President, prospective, range, ranging, real, reconciliation, remeasured, repayment, repurchased, retrospective, secured, Simard, simple, specific, tabular, transparency, understanding, unique, Winnebago

Removed: addendum, allocated, amended, analogized, analogy, asserted, authority, bermekimab, billion, Codification, collect, collected, continued, counterparty, customer, debt, decrease, decreased, delayed, department, determined, distinct, eligible, entitled, entity, eventual, executed, Febuary, fifty, German, good, guidance, HR, ii, iii, intended, iv, largest, manufacture, measured, Measurement, meet, ordinary, output, policy, primary, profitable, promised, raw, receiving, reduction, satisfied, scope, single, small, smaller, stage, standard, terminated, thereof, treatment, VP

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

XBIT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of XBiotech Inc. on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Simard, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc.

	/S/JOHN SIMARD
	John Simard
	Chief Executive Officer and President
	(Principal Executive Officer)
	Date: May 10, 2024

In connection with the Quarterly Report of XBiotech Inc. on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Angela Hu, Director of Finance of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc.

	/S/ ANGELA HU
	Angela Hu
	Director of Finance
	(Principal Financial Officer)
	Date: May 10, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.